Clotilde Boudousq

Clotilde Boudousq

Auto-generated profile, based on publicly available information

Clotilde Boudousq

Department of Ophthalmology, Dijon University Hospital, Dijon, France

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2024 in Ophthalmology Retina
Verified
Journal Article
Open access
CBClotilde Boudousq
Clotilde Boudousq
VNVuong Nguyen
Vuong Nguyen
AHAdrian Hunt
Adrian Hunt
MGMark C. Gillies
Mark C. Gillies
JZJavier Zarranz-Ventura
Javier Zarranz-Ventura
Pierre-Henry GabriellePierre-Henry Gabrielle
Pierre-Henry Gabrielle
To evaluate the proportion, predictors and outcomes of neovascular age-related macular degeneration (nAMD) patients treated with a high burden of vascular endothelial growth factor (VEGF) inhibitor injections (IVT) after two years in routine clinical practice. Retrospective analysis of data from a prospectively designed observational outcomes registry, Fight Retinal Blindness! project, of patients treated in European centers. Treatment-naïve eyes (one eye per patient) starting VEGF inhibitors for nAMD from January 2017 to March 2020 with 24 months of follow-up. We analyzed three treatment burden groups defined by the mean interval of the three closest injections to the 24-month visit: (1) those with a high treatment burden had injection intervals ≤ 42 days, (2) those with a low treatment burden had injection intervals between 43 and 83 days and those with tolerable treatment burden had injection intervals between 84 and 365 days. Multinomial regression was used to evaluate baseline risk predictors of patients requiring a high treatment burden. The proportion of patients that experienced a high treatment burden at 2 years and its predictors. We identified 2,038 eligible patients completing 2 years of treatment (2038/3943 patients [60%]) with a median (Q1, Q3) of 13 (10, 17) injections. The proportion of patients with a high treatment burden was 25% (516 patients) at 2 years. Younger patients (Odds ratio (OR), 0.97; 95%CI, 0.96-0.99; P<0.01) were more likely to have high treatment burden, while eyes with type 3 CNV at baseline were significantly less likely (OR, 0.26; 95%CI, 0.13-0.52; P<0.01). Regarding type of fluid, patients with subretinal fluid only at baseline (OR, 3.85; 95%CI, 1.34-11.01; P=0.01) and persistent active intraretinal (OR, 1.56; 95%CI, 1.18-2.06; P<0.01) or subretinal fluid only (OR, 2.21; 95%CI, 1.52-3.21; P<0.01) after the loading phase had a higher risk of high treatment burden at 2 years. High treatment burden is common issue in routine clinical practice in Europe, with a quarter of patients requiring injections of conventional VEGF inhibitors every 6 weeks at 2 years and 40 percent discontinuing treatment within 2 years.

21 October 2023 in Journal Français d'Ophtalmologie
Verified
Journal Article
Closed access
CBC. Boudousq
C. Boudousq
PEP. Eid
P. Eid
LAL. Arnould
L. Arnould
IGI. Ben Ghezala
I. Ben Ghezala
ABAlain Bron
Alain Bron
PGP.-H. Gabrielle
P.-H. Gabrielle